Ab­b­Vie’s $8.7B neu­ro gam­bit; Land­mark sick­le cell ap­provals; Roche buys a GLP-1 com­pa­ny; End­points 100 biotech sur­vey; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

What a week! News has tru­ly been fir­ing on all cylin­ders, and our team is proud to present not just the break­ing sto­ries but sec­ond-day analy­ses of what they mean. If you’re in­to hema­tol­ogy, do check the web­site over the week­end for Max Gel­man and Lei Lei Wu’s live cov­er­age of ASH. Al­ter­na­tive­ly, we will catch you up on Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER